Podcast #70 ProMIS Neurosciences Inc. CEO Dr. Elliot Goldstein

Two major pharmaceutical companies developing advanced-stage R&D on Alzheimer’s disease have just pulled the plug on their research. The reason why their approach to Alzheimer’s, Aducanumab, failed is because it didn’t account for a factor that is central
to R&D conducted by biotechnology Company ProMIS Neurosciences Inc.
(TSX:PMN, OTCQB:ARFXF, Forum).

Preclinical studies show the Company's lead antibody candidate, PMN310,
demonstrates a high degree of binding to toxic oligomers from Alzheimer's disease brains without binding to plaque or other non-toxic forms of the toxic oligomer form of
amyloid beta (Aβ).

Not only has an important competitor dropped out of the race to find an Alzheimer’s
treatment, the reason for failure suggests that ProMis is on the right track with its own
research.

Stockhouse is joined by Company President and CEO, Dr. Elliot Goldstein to learn
more about ProMIS’ research and potential to combat Alzheimer’s Disease.